Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

Looking good here.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
David Fowler Member Profile
 
Followed By 39
Posts 6,242
Boards Moderated 0
Alias Born 11/30/10
160x600 placeholder
NanoViricides reports strong pre-clinical data for COVID-19 drugs Seeking Alpha - 3/9/2021 11:26:50 AM
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont InvestorsHub NewsWire - 3/9/2021 9:30:00 AM
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical InvestorsHub NewsWire - 3/2/2021 7:00:08 AM
NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies Seeking Alpha - 3/2/2021 6:43:58 AM
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont InvestorsHub NewsWire - 2/17/2021 7:00:00 AM
NanoViricides reports FQ2 results Seeking Alpha - 2/17/2021 6:28:57 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/16/2021 4:40:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 9:48:43 AM
NanoViricides’s anti-coronavirus candidate was well tolerated in animal studies Seeking Alpha - 2/8/2021 6:46:46 AM
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C... InvestorsHub NewsWire - 2/8/2021 6:36:27 AM
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants InvestorsHub NewsWire - 1/27/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/26/2021 11:05:24 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2021 11:45:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/10/2020 4:31:33 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/3/2020 4:31:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 4:53:44 PM
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA InvestorsHub NewsWire - 11/19/2020 6:47:01 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 4:33:46 PM
NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 InvestorsHub NewsWire - 11/11/2020 7:14:53 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/26/2020 4:25:50 PM
Annual Report (10-k) Edgar (US Regulatory) - 10/13/2020 5:23:45 PM
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 InvestorsHub NewsWire - 9/16/2020 7:17:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/3/2020 5:20:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/31/2020 5:30:54 PM
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 InvestorsHub NewsWire - 7/21/2020 9:42:43 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences